PRLDPrelude Therapeutics Inc
PRLD
Prelude Therapeutics Inc1,166
Mkt Cap
$283.51MVolume
108,148.0052W High
$5.5452W Low
$0.75PE Ratio
-4.10PRLD Fundamentals
Price
$4.31Prev Close
$4.33Open
$4.4250D MA
$4.13Beta
1.94Avg. Volume
477,246.35EPS (Annual)
-$1.29P/B
4.53Rev/Employee
$153,670.89$137.75
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Prelude Therapeutics (PRLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Given Consensus Recommendation of "Hold" by Analysts
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) has earned an average rating of 'Hold' from the five brokerages that are presently covering the stock, Marketbeat.com reports. One...
Prelude Therapeutics (NASDAQ:PRLD) Coverage Initiated by Analysts at D. Boral Capital
D. Boral Capital initiated coverage on shares of Prelude Therapeutics in a research note on Monday. They set a 'buy' rating and a $9.00 price target on the stock...
Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research
Zacks Research raised Prelude Therapeutics to a "hold" rating in a research report on Tuesday...
Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday
Prelude Therapeutics (NASDAQ:PRLD) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-prelude-therapeutics-incorporated-stock...
HC Wainwright Issues Positive Forecast for Prelude Therapeutics (NASDAQ:PRLD) Stock Price
HC Wainwright upped their price objective on shares of Prelude Therapeutics from $5.00 to $8.00 and gave the stock a "buy" rating in a report on Monday...
Insider Buying: Prelude Therapeutics (NASDAQ:PRLD) Director Acquires 2,815,315 Shares of Stock
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) Director Orbimed Advisors Llc acquired 2,815,315 shares of the business's stock in a transaction on Tuesday, April 21st. The shares...
Prelude Therapeutics (NASDAQ:PRLD) Director Buys $12,499,998.60 in Stock
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) Director Orbimed Advisors Llc acquired 2,815,315 shares of Prelude Therapeutics stock in a transaction that occurred on Tuesday, April 21st. The stock was purchased at an average cost of $4.44 per share, with a total value of...
Prelude Therapeutics (NASDAQ:PRLD) Director David Bonita Buys 2,815,315 Shares
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) Director David Bonita bought 2,815,315 shares of Prelude Therapeutics stock in a transaction on Tuesday, April 21st. The stock was acquired at an average cost of $4.44 per share, for a total transaction of $12,499,998.60. Following...
Prelude Therapeutics Appoints Charles Morris As Chief Medical Officer
(RTTNews) - Prelude Therapeutics Incorporated (PRLD), a clinical-stage precision oncology company, said on Wednesday that Charles Morris will join the company as chief medical officer with effect from April 20...
<
1
2
...
>
Compact View
Not available
Not available